Here are the most recent, relevant findings I can see about Interferon-inducible GTPase 5 (GBP5)—specifically new work published in late 2025 that expands its antiviral mechanism.
Latest update (recent publication)
- A 2025-11-16 study reports that the interferon-stimulated gene GBP5 can inhibit viral N-linked glycosylation as an antiviral mechanism. In experiments using SARS-CoV-2 spike protein as a model glycoprotein, the paper describes how GBP5 interferes with OST-mediated glycosylation, leading to spike misfolding/ER retention and reduced virion assembly and release.[1]
Related background (context)
- GBP5 (a member of the interferon-inducible GTPases) has previously been described as participating in host defense processes against viruses, including reports of restricting retroviruses like HIV-1 (mechanisms including effects on viral envelope glycoprotein processing have been discussed in earlier literature).[3]
If you tell me whether you mean human GBP5 (gene GBP5) and whether you care most about COVID/SARS-CoV-2, HIV, or inflammasome/immune signaling (e.g., NLRP3), I can narrow this to the most relevant “latest news” threads and summarize them.